A note on quantifying follow-up in studies of failure time - PubMed (original) (raw)
A note on quantifying follow-up in studies of failure time
M Schemper et al. Control Clin Trials. 1996 Aug.
No abstract available
Similar articles
- A nonparametric approach to a survival study with surrogate endpoints.
Walker S. Walker S. Biometrics. 1998 Jun;54(2):662-72. Biometrics. 1998. PMID: 9660632 - Breaking down barriers: helpful breakthrough statistical methods you need to understand better.
Blackstone EH. Blackstone EH. J Thorac Cardiovasc Surg. 2001 Sep;122(3):430-9. doi: 10.1067/mtc.2001.117536. J Thorac Cardiovasc Surg. 2001. PMID: 11547291 Review. No abstract available. - Power comparisons for group sequential tests with nonparametric statistics in case of nonproportional hazards.
Demirhan H, Demirhan YP, Bacanli S. Demirhan H, et al. J Biopharm Stat. 2013 Mar 11;23(2):447-60. doi: 10.1080/10543406.2011.616975. J Biopharm Stat. 2013. PMID: 23437950 - Missing cause of death information in the analysis of survival data.
Andersen J, Goetghebeur E, Ryan L. Andersen J, et al. Stat Med. 1996 Oct 30;15(20):2191-201. doi: 10.1002/(SICI)1097-0258(19961030)15:20<2191::AID-SIM358>3.0.CO;2-D. Stat Med. 1996. PMID: 8910963 - Survival analysis in public health research.
Lee ET, Go OT. Lee ET, et al. Annu Rev Public Health. 1997;18:105-34. doi: 10.1146/annurev.publhealth.18.1.105. Annu Rev Public Health. 1997. PMID: 9143714 Review.
Cited by
- The long-term conditional mortality rate in older ICU patients compared to the general population.
Aronsson Dannewitz A, Svennblad B, Michaëlsson K, Lipcsey M, Gedeborg R. Aronsson Dannewitz A, et al. Crit Care. 2024 Nov 14;28(1):368. doi: 10.1186/s13054-024-05147-z. Crit Care. 2024. PMID: 39543756 Free PMC article. - Donor Time to Death and Kidney Transplant Outcomes in the Setting of a 3-Hour Minimum Wait Policy.
Tingle SJ, Chung NDH, Malik AK, Kourounis G, Thompson E, Glover EK, Mehew J, Philip J, Gardiner D, Pettigrew GJ, Callaghan C, Sheerin NS, Wilson CH. Tingle SJ, et al. JAMA Netw Open. 2024 Nov 4;7(11):e2443353. doi: 10.1001/jamanetworkopen.2024.43353. JAMA Netw Open. 2024. PMID: 39541122 Free PMC article. - Real-world effectiveness of CDK 4/6 inhibitors in estrogen-positive metastatic breast cancer.
Gehrchen ML, Berg T, Garly R, Jensen MB, Eßer-Naumann S, Rønlev JD, Nielsen HM, Knoop A, Kümler I. Gehrchen ML, et al. BJC Rep. 2024 Jun 20;2(1):44. doi: 10.1038/s44276-024-00070-w. BJC Rep. 2024. PMID: 39516670 Free PMC article. - Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study.
Hektoen HH, Tsuruda KM, Fjellbirkeland L, Nilssen Y, Brustugun OT, Andreassen BK. Hektoen HH, et al. Br J Cancer. 2024 Nov 3. doi: 10.1038/s41416-024-02895-1. Online ahead of print. Br J Cancer. 2024. PMID: 39489879 - Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis? A EUSTAR analysis.
Wyss A, Jordan S, Graf N, Carreira PE, Distler J, Cerinic MM, Siegert E, Henes J, Zanatta E, Riccieri V, Truchetet ME, Oksel F, Li M, Kucharz EJ, Eyerich K, Del Galdo F, Vonk MC, Vold AH, Gabrielli A, Distler O; EUSTAR collaborators. Wyss A, et al. Arthritis Res Ther. 2024 Oct 31;26(1):187. doi: 10.1186/s13075-024-03418-2. Arthritis Res Ther. 2024. PMID: 39482761 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources